

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:02:54 ON 23 MAY 2006

=> file medline embase biosis caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 15:03:07 ON 23 MAY 2006

FILE 'EMBASE' ENTERED AT 15:03:07 ON 23 MAY 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:03:07 ON 23 MAY 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 15:03:07 ON 23 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s skeletal and muscle and damage
L1 9377 SKELETAL AND MUSCLE AND DAMAGE

=> s l1 and assay
L2 526 L1 AND ASSAY

=> s l2 and (skeletal(w)troponin(w)I or skeletal(w)myosin(w)light(w)chain or
skeletal(w)troponin(w)C or skeletal(w)alpha(w)actinin)
L3 13 L2 AND (SKELETAL(W) TROPONIN(W) I OR SKELETAL(W) MYOSIN(W)
LIGHT(W) CHAIN OR SKELETAL(W) TROPONIN(W) C OR SKELETAL(W) ALPHA
(W) ACTININ)

=> dup rem
ENTER L# LIST OR (END):s3
S3 IS NOT VALID HERE
The L-number entered has not been defined in this session, or it
has been deleted. To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> dup rem
ENTER L# LIST OR (END):l3
PROCESSING COMPLETED FOR L3
L4 6 DUP REM L3 (7 DUPLICATES REMOVED)

=> dis ibib abs l4

L4 ANSWER 1 OF 6 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2005454249 MEDLINE

DOCUMENT NUMBER: PubMed ID: 15833785
TITLE: Fast and slow **skeletal troponin**
I in serum from patients with various
skeletal muscle disorders: a pilot study.
AUTHOR: Simpson Jeremy A; Labugger Ralf; Collier Christine; Brison
Robert J; Iscoe Steve; Van Eyk Jennifer E
CORPORATE SOURCE: Department of Physiology, Queen's University, Kingston,
Ontario, Canada.
SOURCE: Clinical chemistry, (2005 Jun) Vol. 51, No. 6, pp. 966-72.
Electronic Publication: 2005-04-15.
Journal code: 9421549. ISSN: 0009-9147.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200509
ENTRY DATE: Entered STN: 27 Aug 2005
Last Updated on STN: 11 Sep 2005
Entered Medline: 9 Sep 2005

AB BACKGROUND: Detection of **skeletal muscle** injury is hampered by a lack of commercially available **assays** for serum markers specific for **skeletal muscle**; serum concentrations of **skeletal troponin I** (sTnI) could meet this need. Moreover, because sTnI exists in 2 isoforms, slow (ssTnI) and fast (fsTnI), corresponding to slow- and fast-twitch **muscles**, respectively, it could provide insight into differential injury/recovery of specific fiber types. The purpose of this study was to investigate whether the 2 isoforms of sTnI and their modified forms are present in the blood of patients with various **skeletal muscle** disorders. METHODS: Serial serum samples were obtained from 25 patients with various **skeletal muscle** injuries. Serum proteins were separated by a modified sodium dodecyl sulfate-polyacrylamide gel electrophoresis protocol followed by Western blotting for sTnI with monoclonal antibodies specific to ssTnI and fsTnI. RESULTS: We observed (a) intact and, in some cases, degraded sTnI products; (b) evidence of posttranslational modifications in addition to proteolysis; and (c) differential detectability of both **skeletal** isoforms in the same patient. CONCLUSIONS: It is possible to monitor both sTnI isoforms; this could lead to the development of new diagnostic **assays** for **skeletal muscle** damage.

=> dis ibib abs l3 1-6

L3 ANSWER 1 OF 13 MEDLINE on STN
ACCESSION NUMBER: 2005454249 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15833785
TITLE: Fast and slow **skeletal troponin**
I in serum from patients with various
skeletal muscle disorders: a pilot study.
AUTHOR: Simpson Jeremy A; Labugger Ralf; Collier Christine; Brison
Robert J; Iscoe Steve; Van Eyk Jennifer E
CORPORATE SOURCE: Department of Physiology, Queen's University, Kingston,
Ontario, Canada.
SOURCE: Clinical chemistry, (2005 Jun) Vol. 51, No. 6, pp. 966-72.
Electronic Publication: 2005-04-15.
Journal code: 9421549. ISSN: 0009-9147.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200509
ENTRY DATE: Entered STN: 27 Aug 2005
Last Updated on STN: 11 Sep 2005
Entered Medline: 9 Sep 2005

AB BACKGROUND: Detection of **skeletal muscle** injury is hampered by a lack of commercially available **assays** for serum markers specific for **skeletal muscle**; serum concentrations of **skeletal troponin I** (sTnI) could meet this need. Moreover, because sTnI exists in 2 isoforms, slow (ssTnI) and fast (fsTnI), corresponding to slow- and fast-twitch **muscles**, respectively, it could provide insight into differential injury/recovery of specific fiber types. The purpose of this study was to investigate whether the 2 isoforms of sTnI and their modified forms are present in the blood of patients with various **skeletal muscle** disorders. METHODS: Serial serum samples were obtained from 25 patients with various **skeletal muscle** injuries. Serum proteins were separated by a modified sodium dodecyl sulfate-polyacrylamide gel electrophoresis protocol followed by Western blotting for sTnI with monoclonal antibodies specific to ssTnI and fsTnI. RESULTS: We observed (a) intact and, in some cases, degraded sTnI products; (b) evidence of posttranslational modifications in addition to proteolysis; and (c) differential detectability of both **skeletal** isoforms in the same patient. CONCLUSIONS: It is possible to monitor both sTnI isoforms; this could lead to the development of new diagnostic **assays** for **skeletal muscle** damage.

L3 ANSWER 2 OF 13 MEDLINE on STN
ACCESSION NUMBER: 96426681 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8828960
TITLE: Use of enzyme immunoassay for measurement of **skeletal troponin-I** utilizing isoform-specific monoclonal antibodies.
AUTHOR: Takahashi M; Lee L; Shi Q; Gawad Y; Jackowski G
CORPORATE SOURCE: Spectral Diagnostics, Inc., Toronto, Ontario, Canada.
SOURCE: Clinical biochemistry, (1996 Aug) Vol. 29, No. 4, pp. 301-8.
Journal code: 0133660. ISSN: 0009-9120.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199702
ENTRY DATE: Entered STN: 27 Feb 1997
Last Updated on STN: 27 Feb 1997
Entered Medline: 11 Feb 1997

AB OBJECTIVE: To determine the serum level of fast **skeletal troponin I** (fsTnI) resulting from **skeletal muscle damage**, we have developed a sensitive two-site enzyme immunoassay to measure **skeletal troponin I**. DESIGN AND METHODS: Twelve monoclonal antibodies were raised against human fsTnI. Of these antibodies, 8 were fsTnI-specific and the remaining 4 reacted with both **skeletal** and cardiac troponin I (cTnI). Two monoclonals were utilized for a development of this fsTnI immunoassay. Standards were made with purified recombinant human fsTnI for the range of 0-25 micrograms/mL. RESULTS: Total **assay** variance (CV) ranged from 1.7% to 9.6%. The upper limit of the normal reference range was established as 0.2 microgram/L by determining fsTnI concentration in sera of 108 healthy donors without evidence of **muscle damage**. Purified human cTnI up to 500 micrograms/L and cTnI-positive clinical serum samples yielded negative results in the fsTnI **assay**. The serum levels of fsTnI were determined in trauma patients, patients with chronic degenerative **muscle** disease, and marathon runners. In the study populations, the serum levels of fsTnI were correlated with other biochemical markers that are traditionally used to monitor striated **muscle damage**. CONCLUSIONS: In the present preliminary studies, measuring the serum levels of fsTnI in patients with various forms of **muscle damage** is more accurate than using the classical non **muscle**-specific biochemical markers.

L3 ANSWER 3 OF 13 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005240815 EMBASE
TITLE: Fast and slow **skeletal troponin I** in serum from patients with various **skeletal muscle disorders**: A pilot study.
AUTHOR: Simpson J.A.; Labugger R.; Collier C.; Brison R.J.; Iscoe S.; Van Eyk J.E.
CORPORATE SOURCE: S. Iscoe, Department of Physiology, Queen's University, Kingston, Ont. K7L 3N6, Canada. iscoes@post.queensu.ca
SOURCE: Clinical Chemistry, (2005) Vol. 51, No. 6, pp. 966-972. .
Refs: 28
ISSN: 0009-9147 CODEN: CLCHAU
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 005 General Pathology and Pathological Anatomy
029 Clinical Biochemistry
033 Orthopedic Surgery
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 30 Jun 2005
Last Updated on STN: 30 Jun 2005

AB Background: Detection of **skeletal muscle injury** is hampered by a lack of commercially available **assays** for serum markers specific for **skeletal muscle**; serum concentrations of **skeletal troponin I (sTnI)** could meet this need. Moreover, because sTnI exists in 2 isoforms, slow (ssTnI) and fast (fsTnI), corresponding to slow- and fast-twitch **muscles**, respectively, it could provide insight into differential injury/recovery of specific fiber types. The purpose of this study was to investigate whether the 2 isoforms of sTnI and their modified forms are present in the blood of patients with various **skeletal muscle disorders**. Methods: Serial serum samples were obtained from 25 patients with various **skeletal muscle injuries**. Serum proteins were separated by a modified sodium dodecyl sulfate-polyacrylamide gel electrophoresis protocol followed by Western blotting for sTnI with monoclonal antibodies specific to ssTnI and fsTnI. Results: We observed (a) intact and, in some cases, degraded sTnI products; (b) evidence of posttranslational modifications in addition to proteolysis; and (c) differential detectability of both **skeletal isoforms** in the same patient. Conclusions: It is possible to monitor both sTnI isoforms; this could lead to the development of new diagnostic **assays for skeletal muscle damage**.
.COPYRGT. 2005 American Association for Clinical Chemistry.

L3 ANSWER 4 OF 13 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004133429 EMBASE
TITLE: [Evaluation of a rapid immunoassay for the quantification of cardiac troponin I in the diagnosis of acute myocardial infarction].
EVALUACION DE UN INMUNOANALISIS RAPIDO DE CUANTIFICACION DE TROPONINA I CARDIACA EN EL DIAGNOSTICO DE INFARTO AGUDO DEL MIOCARDIO.
AUTHOR: Mainet Gonzalez D.; Sorell Gomez L.; Pichardo Diaz D.; Reyes Acosta O.; Torres Cabrera M.B.; Abdo Cuza A.; Castellano Gutierrez R.; Padron Brito N.
CORPORATE SOURCE: D. Mainet Gonzalez, Ctro. Ing. Genet./Biotecnol., Apartado postal 6162, Ciudad Habana 10600, Cuba.
damian.mainet@cigb.edu.cu
SOURCE: Quimica Clinica, (2003) Vol. 22, No. 6, pp. 419-430. .
Refs: 49
ISSN: 1139-2436 CODEN: RSQCFW
COUNTRY: Spain

DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 005 General Pathology and Pathological Anatomy
018 Cardiovascular Diseases and Cardiovascular Surgery
LANGUAGE: Spanish
SUMMARY LANGUAGE: English; Spanish
ENTRY DATE: Entered STN: 12 Apr 2004
Last Updated on STN: 12 Apr 2004

AB Cardiac troponin I is considered the biochemical marker of choice in acute myocardial infarction due to its high cardioespecificity. Twenty one monoclonal antibodies were obtained that recognized several epitopes of the cardiac troponin I in the free form and forming complexes with troponin T and troponin C. We were able to standardize an immunoassay with a duration of less than one hour for the quantification of cardiac troponin I in plasma. The following parameters of the immunoassay were evaluated: inter-assay and intra-assay coefficients were smaller than 10%, limit of detection of 0.1 µg/L, (as percent recovery) accuracy between 90% - 110% and absence of cross reactivity with the skeletal troponin I. The clinical specificity was 100% in the retrospective evaluation of this biochemical marker in healthy donors, patients with unstable angina, patients with chronic renal failure and patients with skeletal muscle damage. The clinical sensitivity was 100% from 24 to 48 hours and 98,2% from 6 to 48 hours from the onset of chest pain in patients with acute myocardial infarction. For these reasons, this immunoassay fulfills the recommendations suggested by the international committee of standardization of this biochemical marker for the use in coronary cares units.

L3 ANSWER 5 OF 13 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 97300602 EMBASE
DOCUMENT NUMBER: 1997300602
TITLE: Analytical performance and clinical utility of a sensitive immunoassay for determination of human cardiac troponin I.
AUTHOR: Davies E.; Gawad Y.; Takahashi M.; Shi Q.; Lam P.; Styba G.; Lau A.; Heesch C.; Usategui M.; Jackowski G.
CORPORATE SOURCE: E. Davies, Spectral Diagnostics Inc., 135-2 West Mall, Toronto, Ont. M9C 1C2, Canada
SOURCE: Clinical Biochemistry, (1997) Vol. 30, No. 6, pp. 479-490.

Refs: 28
ISSN: 0009-9120 CODEN: CLBIAS

PUBLISHER IDENT.: S 0009-9120(97)00111-2
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 16 Oct 1997
Last Updated on STN: 16 Oct 1997

AB Objectives: To determine the serum and plasma level of human cardiac troponin I (cTnI) resulting from myocardial damage, we have developed a sensitive and specific one-step enzyme immunoassay to measure cardiac troponin I. Design and Methods: The COBAS® cTnI assay is a semi-automated one-step solid phase immunoassay compatible with the COBAS® Core. The assay is performed in a sandwich type format using a polyclonal goat antibody capture and two highly specific horseradish peroxidase conjugated monoclonal antibody detectors directed against different epitopes of the cTnI molecule. Calibrators were made with purified recombinant cTnI. Results: The level of cTnI was determined in 84 healthy donors with no evidence of myocardial injury, resulting in a lower limit of detection (LLD) of 0.09 µg/L. The upper reference limit (URL) of the normal reference range was calculated as 0.20 µg/L. The dynamic range of the consequent EIA was between 0.09 and 6.0 µg/L with a total assay time of 45 min. Intra-assay and inter-

assay variances (CVs) were $\leq 4\%$. Cross-reactivity with fast and slow **skeletal troponin I** was absent in concentrations up to 2.0 mg/L. Common interferents yielded negative results in the cTnI assay. Clinical utility was confirmed by measuring the circulating serum or plasma levels of cardiac troponin I in serial samples from marathon runners, clinical samples from trauma patients, and patients presenting to the Emergency Department with complaints of chest pain. Results were further evaluated using clinical diagnosis at discharge and quantified concentrations of other cardiac markers by a Stratus® analyzer and ELISA procedures. Conclusions: Results from normal and clinical samples assayed in-house for cTnI concentrations indicate that the Spectral EIA is a highly sensitive means of quantifying cTnI levels in serum and plasma for acute cardiac syndrome. The cardiac specificity of cTnI over other well-known cardiac markers is reflected in experimental results and parallel clinical diagnosis.

L3 ANSWER 6 OF 13 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 96227677 EMBASE

DOCUMENT NUMBER: 1996227677

TITLE: Use of enzyme immunoassay for measurement of **skeletal troponin-I** utilizing isoform-specific monoclonal antibodies.

AUTHOR: Takahashi M.; Lee L.; Shi Q.; Gawad Y.; Jackowski G.

CORPORATE SOURCE: Spectral Diagnostics, Inc., 135 West Mall, Toronto, Ont. M9C 1C2, Canada

SOURCE: Clinical Biochemistry, (1996) Vol. 29, No. 4, pp. 301-308.

ISSN: 0009-9120 CODEN: CLBIAS

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 008 Neurology and Neurosurgery
029 Clinical Biochemistry

August

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 7 Oct 1996

Last Updated on STN: 7 Oct 1996

AB Objectives: To determine the serum level of fast **skeletal troponin I** (fsTnI) resulting from **skeletal muscle damage**, we have developed a sensitive two-site enzyme immunoassay to measure **skeletal troponin I**. Design and Methods: Twelve monoclonal antibodies were raised against human fsTnI. Of these antibodies, 8 were fsTnI-specific and the remaining 4 reacted with both **skeletal** and cardiac troponin I (cTnI). Two monoclonals were utilized for a development of this fsTnI immunoassay. Standards were made with purified recombinant human fsTnI for the range of 0-25 µg/mL. Results: Total assay variance (CV) ranged from 1.7% to 9.6%. The upper limit of the normal reference range was established as 0.2 µg/L by determining fsTnI concentration in sera of 108 healthy donors without evidence of **muscle damage**. Purified human cTnI up to 500 µg/L and cTnI-positive clinical serum samples yielded negative results in the fsTnI assay. The serum levels of fsTnI were determined in trauma patients, patients with chronic degenerative **muscle** disease, and marathon runners. In the study populations, the serum levels of fsTnI were correlated with other biochemical markers that are traditionally used to monitor striated **muscle damage**. Conclusions: In the present preliminary studies, measuring the serum levels of fsTnI in patients with various forms of **muscle damage** is more accurate than using the classical non **muscle**-specific biochemical markers.

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

Connecting via Winsock to STN

Welcome to STN International! Enter x:

x

Welcome to STN International! Enter x:

LOGINID:ssptacmb1647

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	4	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	5	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	6	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	7	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	8	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	9	MAR 22	EMBASE is now updated on a daily basis
NEWS	10	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS	11	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS	12	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	13	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS	14	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS	15	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS	16	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	17	MAY 11	KOREAPAT updates resume
NEWS	18	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS EXPRESS			FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * *

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

FULL ESTIMATED COST 51.18 51.39

FILE 'STNGUIDE' ENTERED AT 15:07:14 ON 23 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 19, 2006 (20060519/UP).

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
1.26	52.65

FULL ESTIMATED COST

STN INTERNATIONAL LOGOFF AT 15:19:46 ON 23 MAY 2006